The Eila® clinical trial, part of the Alex Therapeutics and Pfizer partnership to provide evidence-based Digital Therapeutics to patients in Germany, has reached its first major recruitment milestone.
‍

The Eila® study, number X9001304, is a prospective, comparative, randomized, single-blind, multicenter, pragmatic clinical study with approximately 1,000 participants in Germany, designed to assess the safety and effectiveness of the Eila® DTx compared to the standard of care. The medical device was developed by Alex Therapeutics and adapted to the requirements of the German healthcare system together with Pfizer. Pfizer is conducting the trial in Germany to further validate the medical benefits of the solution.
‍

Eila® is a 12-week program for the treatment of tobacco dependence. The program is based on Acceptance & Commitment Therapy (ACT), an action-oriented psychotherapy with it’s foundation in Cognitive Behavioral Therapy (CBT). The DTx is currently undergoing clinical trial in Germany as part of a strategic collaboration between Alex Therapeutics and Pfizer working to provide evidence-based, clinically validated, and personalized digital therapies to patients. The partnership initially focuses on Germany, one of the world’s largest unified healthcare markets. The recruitment for the Eila® trial will continue with the goal of recruiting 1000 patients in total. In parallel, interim reports will be prepared as major recruitments milestone, such as the one now reached, are met.
‍

John Drakenberg, CEO at Alex Therapeutics, emphasizes his great excitement about this milestone and collaboration with Pfizer.

“We’re excited to have reached this major milestone. Tobacco dependence is a global problem, and we look forward to being able to provide patients with our innovative and dependable digital therapy.”